KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Common Equity (2016 - 2025)

Rigel Pharmaceuticals has reported Common Equity over the past 16 years, most recently at $391.5 million for Q4 2025.

  • For Q4 2025, Common Equity rose 11806.33% year-over-year to $391.5 million; the TTM value through Dec 2025 reached $391.5 million, up 11806.33%, while the annual FY2025 figure was $391.5 million, 11806.33% up from the prior year.
  • Common Equity for Q4 2025 was $391.5 million at Rigel Pharmaceuticals, up from $117.6 million in the prior quarter.
  • Over five years, Common Equity peaked at $391.5 million in Q4 2025 and troughed at -$31.8 million in Q3 2023.
  • A 5-year average of $31.0 million and a median of -$194500.0 in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: plummeted 664.62% in 2023 and later surged 11806.33% in 2025.
  • Year by year, Common Equity stood at $30.4 million in 2021, then crashed by 144.83% to -$13.6 million in 2022, then plummeted by 110.37% to -$28.6 million in 2023, then skyrocketed by 111.48% to $3.3 million in 2024, then surged by 11806.33% to $391.5 million in 2025.
  • Business Quant data shows Common Equity for RIGL at $391.5 million in Q4 2025, $117.6 million in Q3 2025, and $81.9 million in Q2 2025.